Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance
出版年份 2022 全文链接
标题
Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance
作者
关键词
-
出版物
Frontiers in Oncology
Volume 12, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2022-10-27
DOI
10.3389/fonc.2022.1020011
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma
- (2022) Johannes M. Waldschmidt et al. LEUKEMIA
- Deubiquitylase USP12 induces pro-survival autophagy and bortezomib resistance in multiple myeloma by stabilizing HMGB1
- (2022) Hui Li et al. ONCOGENE
- Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes
- (2022) Mark Bustoros et al. Nature Communications
- The molecular make up of smoldering myeloma highlights the evolutionary pathways leading to multiple myeloma
- (2021) Eileen M. Boyle et al. Nature Communications
- Venetoclax sensitivity in multiple myeloma is associated with B cell gene expression
- (2021) Vikas A Gupta et al. BLOOD
- Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma
- (2021) Matteo C. Da Vià et al. NATURE MEDICINE
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
- (2021) Mehmet Kemal Samur et al. Nature Communications
- Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study
- (2021) Bernard Regidor et al. ANNALS OF HEMATOLOGY
- Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities
- (2021) Bénedith Oben et al. Nature Communications
- Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma – a meta-analysis of 2,596 trial patients
- (2021) Niels Weinhold et al. HAEMATOLOGICA
- mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3-and Blimp-1-mediated BCL-2 up-regulation
- (2021) Naoki Osada et al. HAEMATOLOGICA
- Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
- (2021) Nizar J. Bahlis et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs
- (2021) J. R. Jones et al. LEUKEMIA
- Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
- (2021) A. Visram et al. Blood Cancer Journal
- Multiple Myeloma Relapse Is Associated with Increased NFκB Pathway Activity and Upregulation of the Pro-Survival BCL-2 Protein BFL-1
- (2021) Ingrid Spaan et al. Cancers
- Circulating Tumor Cells (CTCs) in Smoldering and Active Multiple Myeloma (MM): Mechanism of Egression, Clinical Significance and Therapeutic Endpoints
- (2021) Juan-José Garcés et al. BLOOD
- Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity
- (2021) Katia Todoerti et al. Cancers
- Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
- (2021) Kristine A. Frerichs et al. Blood Advances
- Expression, mutation, and methylation of crbn‐pathway genes at pre‐ and post‐lenalidomide treatment in multiple myeloma
- (2020) Takuto Tachita et al. CANCER SCIENCE
- Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma
- (2020) Kwan Yeung Wong et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Patterns of somatic structural variation in human cancer genomes
- (2020) Yilong Li et al. NATURE
- Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma
- (2020) Richa Bajpai et al. Nature Communications
- Normalization of serum B‐cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatment
- (2020) Scott Jew et al. BRITISH JOURNAL OF HAEMATOLOGY
- Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression
- (2020) Mark Bustoros et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma
- (2020) Juan-José Garcés et al. LEUKEMIA
- Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes
- (2020) Carolane Seiller et al. Cell Death & Disease
- Multiple Cereblon genetic changes associate with acquired resistance to Lenalidomide or Pomalidomide in Multiple Myeloma
- (2020) Sarah Gooding et al. BLOOD
- JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications
- (2020) Daisuke Ogiya et al. BLOOD
- International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
- (2020) María-Victoria Mateos et al. Blood Cancer Journal
- Natural history of multiple myeloma patients refractory to venetoclax: A single center experience
- (2020) Kathryn T. Maples et al. AMERICAN JOURNAL OF HEMATOLOGY
- Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
- (2020) Shaji K Kumar et al. LANCET ONCOLOGY
- Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data
- (2020) Gurbakhash Kaur et al. Clinical Lymphoma Myeloma & Leukemia
- BCL2 blockade overcomes MCL1 resistance in multiple myeloma
- (2019) Ka Tat Siu et al. LEUKEMIA
- Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma
- (2019) Shannon M. Matulis et al. LEUKEMIA
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
- (2019) Esperanza M Algarín et al. HAEMATOLOGICA
- Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells
- (2019) Haiming Chen et al. LEUKEMIA RESEARCH
- MYC dysregulation in the progression of multiple myeloma
- (2019) Kristine Misund et al. LEUKEMIA
- Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
- (2018) Brian A. Walker et al. BLOOD
- Ligand-mediated protein degradation reveals functional conservation among sequence variants of the CUL4-type E3 ligase substrate receptor cereblon
- (2018) Afua A. Akuffo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression
- (2018) Carlos Fernández de Larrea et al. LEUKEMIA
- Spectrum and functional validation of PSMB5 mutations in multiple myeloma
- (2018) Santiago Barrio et al. LEUKEMIA
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
- (2018) Meletios A. Dimopoulos et al. HAEMATOLOGICA
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
- (2018) Andrew Spencer et al. HAEMATOLOGICA
- Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS
- (2018) Xiaozhong Qian et al. LEUKEMIA & LYMPHOMA
- CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
- (2018) Niels W.C.J. van de Donk et al. Frontiers in Immunology
- BH3-mimetic toolkit guides the respective use of BCL2 and MCL1 BH3-mimetics in myeloma treatment
- (2018) Patricia Gomez-Bougie et al. BLOOD
- Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)
- (2018) L. Sanoja-Flores et al. Blood Cancer Journal
- CD38-negative relapse in multiple myeloma after daratumumab-based chemotherapy
- (2017) Jiri Minarik et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner
- (2017) Konstantinos Dimopoulos et al. Molecular Oncology
- Proteasome inhibitors in cancer therapy
- (2017) Elisabet E. Manasanch et al. Nature Reviews Clinical Oncology
- Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma
- (2016) N. Weinhold et al. BLOOD
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
- (2016) K. M. Kortum et al. BLOOD
- Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma
- (2016) Emily Rychak et al. BRITISH JOURNAL OF HAEMATOLOGY
- Loss of CD38 Expression in Relapsed Refractory Multiple Myeloma
- (2016) Mikiko Ise et al. Clinical Lymphoma Myeloma & Leukemia
- Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
- (2016) S. J. de Haart et al. HAEMATOLOGICA
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- (2016) Michael Ghermezi et al. HAEMATOLOGICA
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Trends in overall survival and costs of multiple myeloma, 2000–2014
- (2016) R Fonseca et al. LEUKEMIA
- Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression
- (2016) W I Gonsalves et al. LEUKEMIA
- Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
- (2016) E. A. Punnoose et al. MOLECULAR CANCER THERAPEUTICS
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma
- (2016) P Ravi et al. Blood Cancer Journal
- Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy
- (2016) Dominik Dytfeld et al. Oncotarget
- Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance
- (2016) S. J. de Haart et al. HAEMATOLOGICA
- Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
- (2016) Michael Ghermezi et al. HAEMATOLOGICA
- Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
- (2015) Brian A. Walker et al. JOURNAL OF CLINICAL ONCOLOGY
- Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax
- (2015) S M Matulis et al. LEUKEMIA
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Clock-like mutational processes in human somatic cells
- (2015) Ludmil B Alexandrov et al. NATURE GENETICS
- γ-secretase directly sheds the survival receptor BCMA from plasma cells
- (2015) Sarah A. Laurent et al. Nature Communications
- Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
- (2015) Diego Acosta-Alvear et al. eLife
- Quantification of clonal circulating plasma cells in relapsed multiple myeloma
- (2014) Wilson I. Gonsalves et al. BRITISH JOURNAL OF HAEMATOLOGY
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone
- (2014) E M Ocio et al. LEUKEMIA
- Extramedullary myeloma whole genome sequencing reveals novel mutations in Cereblon, proteasome subunit G2 and the glucocorticoid receptor in multi drug resistant disease
- (2013) Jan B. Egan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN
- (2013) Anita K. Gandhi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma
- (2013) Chungyee Leung-Hagesteijn et al. CANCER CELL
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
- (2013) C Touzeau et al. LEUKEMIA
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- IMWG consensus on risk stratification in multiple myeloma
- (2013) W J Chng et al. LEUKEMIA
- The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma
- (2013) Elisabet E. Manasanch et al. LEUKEMIA & LYMPHOMA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma
- (2012) B. A. Walker et al. BLOOD
- Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma
- (2012) D. J. Kuhn et al. BLOOD
- Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide
- (2012) A Lopez-Girona et al. LEUKEMIA
- Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients
- (2011) F. Magrangeas et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy
- (2011) Patricia Balsas et al. LEUKEMIA RESEARCH
- Initial genome sequencing and analysis of multiple myeloma
- (2011) Michael A. Chapman et al. NATURE
- Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients
- (2010) A. Broyl et al. BLOOD
- Racial disparities in incidence and outcome in multiple myeloma: a population-based study
- (2010) A. J. Waxman et al. BLOOD
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
- (2009) O. Landgren et al. BLOOD
- Multiple myeloma
- (2008) R. A. Kyle et al. BLOOD
- Evolution and Function of the ADP Ribosyl Cyclase/CD38 Gene Family in Physiology and Pathology
- (2008) Fabio Malavasi et al. PHYSIOLOGICAL REVIEWS
- Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma
- (2007) A. Dispenzieri et al. BLOOD
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search